Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
The objective of this report is to review new evidence on the clinical and safety aspects of mitoxantrone treatment in multiple sclerosis (MS) patients since the original Technology Assessment Unit (TAU) report of December 2002.

Authors' conclusions
Since the last report no new evidence indicating more substantial or more permanent benefit of mitoxantrone treatment in a general MS population has been identified.

Further evidence of cardiotoxicity even at relatively low doses has been identified. There are also new reports suggesting increased risk of leukemia.

Three recent case studies report excellent results of mitoxantrone induction treatment in patients with highly aggressive forms of MS but suffer from a lack of any comparator group.

For these reasons the present indications for use of mitoxantrone in MS should be reconsidered.

Project page URL

Indexing Status
Subject indexing assigned by CRD

MeSH
Costs and Cost Analysis; Mitoxantrone; Multiple Sclerosis /drug therapy

Language Published
French

Country of organisation
Canada

Province or state
Quebec

Address for correspondence
Technology Assessment Unit of the MUHC, Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, 5252 boul. de Maisonneuve, Bureau 3F.50, Montreal, Quebec H4A 3S5 Email: nandini.dendukuri@mcgill.ca

AccessionNumber